Nuklearmedizin 2022; 61(05): 414-415
DOI: 10.1055/a-1809-4570
Case Report

Discrepancy of PSMA PET imaging and bone scan showing limited value of bone scan and CT in evaluation of extent of bone involvement

Diskrepanz zwischen PSMA-PET-Bildgebung und Knochenszintigraphie zeigt eine begrenzte Wertigkeit der Knochenszintigraphie und CT bei der Beurteilung des Ausmaßes der Knochenbeteiligung
Daniel Alexander Hescheler
1   Nuclear Medicine, Universitätsklinikum Münster, Munster, Germany (Ringgold ID: RIN39069)
,
Lars Stegger
2   Nuclear Medicine, University Hospital Munster, Munster, Germany (Ringgold ID: RIN39069)
,
Katrin Schlack
3   Urology, Universitätsklinikum Münster, Munster, Germany (Ringgold ID: RIN39069)
,
Martin Bögemann
4   Urology, Universitatsklinikum Munster, Muenster, Germany (Ringgold ID: RIN39069)
,
Kambiz Rahbar
5   Nuclear medicine, University Hospital Muenster, Muenster, Germany
› Author Affiliations


Publication History

Received: 01 December 2021

Accepted after revision: 25 March 2022

Article published online:
11 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Budd RS, Hodgson GS, Hare WS. et al. The relation of radionuclide uptake by bone to the rate of calcium mineralization. II: Patient studies using 99Tcm-MDP. Br J Radiol 1989; 62: 318-320
  • 2 Poeppel. et al. “EANM guideline for radionuclide therapy with radium-223 of metastatic tration-resistant prostate cancer”. European Journal of Nuclear Medicine and Molecular Imaging 2018; 45: 824-845
  • 3 Bräuer. et al. “Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma”. Nuklearmedizin 2017; 56 (01) 14-22
  • 4 Hartrampf. et al. “Pitfalls in PSMA-PET/CT: intensive bone marrow uptake in a case with polycythemia vera”. European Journal of Nuclear Medicine and Molecular Imaging 2021; 48: 1669-1670
  • 5 Kunikowska J, Pełka K. “Myelofibrosis Pattern in 68Ga-PSMA PET/CT of a Patient With Recurrence Prostate Cancer”. Clinical Nuclear Medicine 2022; 47 (02) e182-e183